Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial -

Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial
Information type: Randomised controlled trials
Source: The Lancet Infectious Diseases
Specialities: Infection and infectious diseases | Sexual health
Summary
This RCT (n=261) reports single dose oral solithromycin 1g did not meet the criterion for non-inferiority when compared to oral azithromycin plus iv ceftriaxone for the treatment of N gonorrhoeae (80% vs 84% eradication at test of cure, difference -4%, 95% CI −13.6 to 5.5).
UKMi comment

In a related editorial, the authors suggest that a different dosing regimen (i.e. longer duration) for solithromycin may need to be investigated; in light of the increased gastrointestinal adverse effects reported in this trial, a higher single dose of solithromycin was not an option.
Related links: Comment